Hamre Harald Johan, Kiene Helmut, Ziegler Renatus, Tröger Wilfried, Meinecke Christoph, Schnürer Christof, Vögler Hendrik, Glockmann Anja, Kienle Gunver Sophia
Institute for Applied Epistemology and Medical Methodology at the University of Witten-Herdecke, Freiburg, Germany (Dr Hamre).
Institute for Applied Epistemology and Medical Methodology at the University of Witten-Herdecke, Freiburg, Germany (Dr Kienle).
Glob Adv Health Med. 2014 Jan;3(1):54-70. doi: 10.7453/gahmj.2013.010.
Anthroposophic medicine is a physician-provided complementary therapy system that was founded by Rudolf Steiner and Ita Wegman. Anthroposophic therapy includes special medicinal products, artistic therapies, eurythmy movement exercises, and special physical therapies. The Anthroposophic Medicine Outcomes Study (AMOS) was a prospective observational multicenter study of 1631 outpatients starting anthroposophic therapy for anxiety disorders, asthma, attention deficit hyperactivity disorder, depression, low back pain, migraine, and other chronic indications under routine conditions in Germany. AMOS INCORPORATED TWO FEATURES PROPOSED FOR THE EVALUATION OF INTEGRATIVE THERAPY SYSTEMS: (1) a sequential approach, starting with the whole therapy system (use, safety, outcomes, perceived benefit), addressing comparative effectiveness and proceeding to the major system components (physician counseling, anthroposophic medicinal products, art therapy, eurythmy therapy, rhythmical massage therapy) and (2) a mix of different research methods to build an information synthesis, including pre-post analyses, prospective comparative analyses, economic analyses, and safety analyses of individual patient data. AMOS fostered two methodological innovations for the analysis of single-arm therapy studies (combined bias suppression, systematic outcome comparison with corresponding cohorts in other studies) and the first depression cost analysis worldwide comparing primary care patients treated for depression vs depressed patients treated for another disorder vs nondepressed patients. A total of 21 peer-reviewed publications from AMOS have resulted. This article provides an overview of the main research questions, methods, and findings from these publications: anthroposophic treatment was safe and was associated with clinically relevant improvements in symptoms and quality of life without cost increase; improvements were found in all age, diagnosis, and therapy modality groups and were retained at 48-month follow-up; nonrespondent bias, natural recovery, regression to the mean, and adjunctive therapies together could explain a maximum of 37% of the improvement.
人智医学是一种由鲁道夫·施泰纳和伊塔·韦格曼创立的、由医生提供的补充治疗体系。人智疗法包括特殊的医药产品、艺术疗法、优律司美运动练习以及特殊的物理疗法。人智医学结果研究(AMOS)是一项前瞻性观察性多中心研究,研究对象为1631名在德国常规条件下开始接受人智疗法治疗焦虑症、哮喘、注意力缺陷多动障碍、抑郁症、腰痛、偏头痛及其他慢性疾病的门诊患者。AMOS纳入了为评估综合治疗体系而提出的两个特征:(1)一种循序渐进的方法,从整个治疗体系(使用、安全性、结果、感知益处)入手,探讨比较有效性,然后深入到主要的体系组成部分(医生咨询、人智医药产品、艺术疗法、优律司美疗法、节律性按摩疗法);(2)运用多种不同的研究方法来构建信息综合,包括前后分析、前瞻性比较分析、经济分析以及个体患者数据的安全性分析。AMOS促成了单臂治疗研究分析方面的两项方法创新(联合偏倚抑制、与其他研究中的相应队列进行系统结果比较)以及全球首个抑郁症成本分析,该分析比较了接受抑郁症治疗的初级保健患者、因其他疾病接受治疗的抑郁症患者以及非抑郁症患者。AMOS共产生了21篇经过同行评审的出版物。本文概述了这些出版物中的主要研究问题、方法和发现:人智治疗是安全的,且与症状和生活质量在临床上的相关改善相关联,同时没有成本增加;在所有年龄、诊断和治疗方式组中均发现了改善,并且在48个月的随访中得以维持;无反应偏倚、自然康复、均值回归以及辅助疗法共同最多只能解释37%的改善。